FDA Clearance Tracker · P130022-S058
Senza Spinal Cord Stimulation (SCS) System and HFX iQ System
Last checked: Nov 20, 2026Latest source record: Sep 24, 2024 (this decision)Source: openFDAMethods & limitations
Decided
Sep 24, 2024
Approved
Time to decision
180 days
Received Mar 28, 2024. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P130022-S058
- Device name
- Senza Spinal Cord Stimulation (SCS) System and HFX iQ System
- Applicant
- Nevro Corporation
- Applicant location
- Redwood City, CA
- Received
- Mar 28, 2024
- Decided
- Sep 24, 2024
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P130022
Device type
- Device class
- Class III
FDA's approval statement
As written in FDA's record.
Approval for an update to the Clinical Summary manual to add 24-month results from their Senza-PDN study to demonstrate long-term safety and effectiveness of 10 kHz SCS therapy in treating painful diabetic neuropathy (PDN) patients.
Source documents
Other decisions for Nevro Corporation
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Senza Spinal Cord Stimulation (SCS) SystemPMA supplement
P130022-S042 · Decided Jan 18, 2022 · 180 days after receipt · Panel Track
Device type: Stimulator, spinal-cord, totally implanted for pain relief (LGW) · Neurology & Neurosurgery
2 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.